Literature DB >> 2433337

Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.

K Pfizenmaier, P Scheurich, C Schlüter, M Krönke.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) exerts multiple biologic activities, which include such diverse effects as direct tumoricidal activity and stimulation of metabolic activities as well as expression of cell surface antigens on nonmalignant cells. We report here that in various human tumor cells TNF-alpha upregulates constitutively expressed HLA genes. Further, in a priori HLA-negative tumor cells, TNF-alpha enhances IFN-gamma-induced class I and class II HLA gene expression. In vitro transcription, Northern blot, and immunofluorescence analysis performed with the leukemic cell line K 562 reveal that TNF-alpha reversibly enhances IFN-gamma-induced HLA gene expression at the level of mRNA transcription. In addition, a posttranscriptional regulation of HLA gene expression by TNF-alpha is suggested from enhancement of HLA class I membrane expression in Colo 205 cells without measurable changes in steady state mRNA levels. Therefore, it is conceivable that TNF-alpha, similar to IFN-gamma, might provoke tumor rejection not only via direct tumoricidal action but also via enhancement of HLA antigens and induction of tumor-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433337

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  A complex regulatory DNA element associated with a major histocompatibility complex class I gene consists of both a silencer and an enhancer.

Authors:  J D Weissman; D S Singer
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

2.  Luteinization of human granulosa cells in vivo is associated with expression of MHC class II antigens.

Authors:  E L Khoury; L A Marshall
Journal:  Cell Tissue Res       Date:  1990-11       Impact factor: 5.249

3.  Tumour necrosis factor enhances the interferon-gamma-induced class II MHC antigen expression on murine keratinocytes in vivo.

Authors:  K Nakamura; K Tamaki
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  The expression of class I major histocompatibility antigens by human retinal pigment epithelium in vitro.

Authors:  M T Benson; L Shepherd; D Cottam; J Lawry; R C Rees; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

5.  Regulation of the release of tumour necrosis factor (TNF)alpha and soluble TNF receptor by gamma irradiation and interferon gamma in Ewing's sarcoma/peripheral primitive neuroectodermal tumour cells.

Authors:  F van Valen; V Kentrup-Lardong; B Truckenbrod; C Rübe; W Winkelmann; W W Jürgens
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 6.  MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune diseases.

Authors:  C O Jacob; G D Lewis; H O McDevitt
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

7.  MHC class II antigen expression in human vascular smooth muscle cells is induced by interferon-gamma and modulated by tumour necrosis factor and lymphotoxin.

Authors:  S Stemme; G Fager; G K Hansson
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

8.  Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways.

Authors:  T Fujita; L F Reis; N Watanabe; Y Kimura; T Taniguchi; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha.

Authors:  B Meier; H H Radeke; S Selle; M Younes; H Sies; K Resch; G G Habermehl
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

10.  Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G Spanakos; O E Tsitsilonis; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.